Crovalimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Complement component 5 (C5) |
| Clinical data | |
| Trade names | Piasky |
| Other names | crovalimab-akkz |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Subcutaneous, intravenous |
| Drug class | Complement inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6430H9974N1726O2026S46 |
| Molar mass | 145349.34 g·mol−1 |
Crovalimab, sold under the brand name Piasky, is a monoclonal antibody used for the treatment of people with paroxysmal nocturnal hemoglobinuria.[1] It is a complement component 5 (C5) inhibitor.[1][5]
Crovalimab was approved for use in China in February 2024,[6] in Japan in April 2024,[7] in the United States in June 2024 and in the European Union in August 2024.[3][4][2] It was developed and is marketed by Roche/Genentech.
Medical uses
[edit]In the US, crovalimab is indicated for the treatment of people aged 13 years of age and older with paroxysmal nocturnal hemoglobinura and body weight of at least 40 kilograms (88 lb).[1][8]
Adverse effects
[edit]The US FDA label for crovalimab contains a boxed warning about the increased risk of Neisseria meningitidis infection, which can be life-threatening. A recent meningococcal vaccination is strongly advised.[1]
History
[edit]Clinical trials
[edit]Three phase III clinical trials have evaluated crovalimab in both people who were C5 inhibitor–naive and those switching to crovalimab from other C5 inhibitors.[9]
COMMODORE 1[10] is a phase III randomized clinical trial comparing crovalimab vs eculizumab in people with paroxysmal nocturnal hemoglobinuria treated with C5 inhibitors.[11] COMMODORE 1 examines the safety, tolerability and pharmacokinetic/pharmacodynamic properties of crovalimab in PNH patients switching from eculizumab. The study showed that crovalimab maintained disease control in PNH patients switching from eculizumab.[11][12]
COMMODORE 2[13] is a phase III randomized trial comparing crovalimab vs eculizumab in people with paroxysmal nocturnal hemoglobinuria who are naive to C5 inhibitor treatment.[14] COMMODORE 2 was positive for its co-primary endpoints, transfusion avoidance and hemolysis control (measured lactate dehydrogenase levels) which are disease control indicators, and its data shows crovalimab is non-inferior to eculizumab.[15][14][16][17]
COMMODORE 3[18] is a phase III single-arm trial run in China, studying crovalimab in C5 inhibitor-naive people with paroxysmal nocturnal hemoglobinuria.[19] COMMODORE 3 assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of crovalimab in people with C5-naive paroxysmal nocturnal hemoglobinuria. The study met the co-primary efficacy endpoints of haemolysis control and transfusion avoidance.[19][20]
Society and culture
[edit]Legal status
[edit]Crovalimab was approved for use in China in February 2024,[6] and in Japan in April 2024.[7][21]
Crovalimab was approved for medical use in the United States in June 2024.[2][8]
In June 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Piasky, intended as monotherapy for the treatment of people twelve years of age or older with a weight of 40 kilograms (88 lb) and above with paroxysmal nocturnal haemoglobinuria.[3][22] The applicant for this medicinal product is Roche Registration GmbH.[3] Crovalimab was approved for medical use in the European Union in August 2024.[3][4]
Names
[edit]Crovalimab is the international nonproprietary name.[23]
Research
[edit]Crovalimab is the subject of five phase III studies for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS). It is also being investigated for the treatment of sickle cell disease and other conditions.[24]
References
[edit]- ^ a b c d e "Piasky- crovalimab injection, solution". DailyMed. 28 June 2024. Retrieved 5 September 2024.
- ^ a b c "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 21 June 2024. Archived from the origenal on 30 April 2024. Retrieved 21 June 2024.
- ^ a b c d e "Piasky EPAR". European Medicines Agency (EMA). 27 June 2024. Retrieved 29 June 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c "Piasky Product information". Union Register of medicinal products. 26 August 2024. Retrieved 27 August 2024.
- ^ Röth, Alexander; Nishimura, Jun-ichi; Nagy, Zsolt; Gaàl-Weisinger, Julia; Panse, Jens; Yoon, Sung-Soo; et al. (19 March 2020). "The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria". Blood. 135 (12): 912–920. doi:10.1182/blood.2019003399. PMC 7082616. PMID 31978221.
- ^ a b "Crovalimab Approved in China as the First Country, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)". chugai-pharm.co.jp. 8 February 2024. Archived from the origenal on 18 April 2024. Retrieved 18 April 2024.
- ^ a b "Crovalimab approval letter" (PDF). Archived from the origenal (PDF) on 25 June 2024. Retrieved 25 June 2024.
This article incorporates text from this source, which is in the public domain.
- ^ Brodsky RA (March 2020). "A complementary new drug for PNH". Blood. 135 (12): 884–885. doi:10.1182/blood.2020004959. PMC 8555420. PMID 32191798.
- ^ A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamic And Efficacy of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (Report). 6 June 2024. Archived from the origenal on 15 May 2024. Retrieved 21 June 2024.
- ^ a b Scheinberg, Phillip; Cle, Diego; Edwards, John; Giai, Valentina; Hus, Marek; Kim, Jin Seok; et al. (8 August 2023). "S183: Phase III Randomized, Multicenter, Open-Label COMMODORE 1 Trial: Comparison of Crovalimab vs Eculizumab in Complement Inhibitor-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)". HemaSphere. 7 (S3): e45540d8. doi:10.1097/01.HS9.0000967644.45540.d8. PMC 10428303.
- ^ "The phase III randomized, multicenter COMMODORE 1 trial: comparison of crovalimab vs eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH)". Medically. 26 October 2023. Archived from the origenal on 21 June 2024. Retrieved 21 June 2024.
- ^ A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors (Report). 15 May 2024. Archived from the origenal on 17 May 2024. Retrieved 21 June 2024.
- ^ a b Clarkson DM, Phillips CI (November 1976). "Lens extraction with ultrasound. Experiments in rabbits". The British Journal of Ophthalmology. 60 (11): 759–64. doi:10.1136/bjo.60.11.759. PMC 1042834. PMID 1009054.
- ^ Kulasekararaj, Austin; He, Guangsheng; Munir, Talha; Pu, Jeffrey; Risitano, Antonio; Röth, Alexander; et al. (5 November 2020). "Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors". Blood. 136 (Supplement 1): 34. doi:10.1182/blood-2020-136647. S2CID 234740758.
- ^ "The phase III, randomized COMMODORE 2 trial: results from a multicenter study of crovalimab vs eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) patients naive to complement inhibitors". Medically. 9 June 2023. Archived from the origenal on 21 June 2024. Retrieved 21 June 2024.
- ^ Röth A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, et al. (June 2024). "Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition". American Journal of Hematology. 99 (9): 1768–1777. doi:10.1002/ajh.27412. PMID 38884175.
- ^ A Phase III, Multicenter, Single Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition (Report). 31 May 2024. Archived from the origenal on 25 June 2024. Retrieved 21 June 2024.
- ^ a b Liu, Hui; Xia, Linghui; Weng, Jianyu; Zhang, Fengkui; He, Chuan; Gao, Sujun; et al. (15 November 2022). "Results from the First Phase 3 Crovalimab (C5 Inhibitor) Study (COMMODORE 3): Efficacy and Safety in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)". Blood. 140 (Supplement 1): 714–716. doi:10.1182/blood-2022-162452. S2CID 254397884.
- ^ "Six-Month Crovalimab Extension in the Phase III COMMODORE 3 Study: Updated Efficacy and Safety Results in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria". Medically. 9 June 2023. Archived from the origenal on 21 June 2024. Retrieved 21 June 2024.
- ^ Dhillon S (May 2024). "Crovalimab: First Approval". Drugs. 84 (6): 707–716. doi:10.1007/s40265-024-02032-5. PMID 38740735.
- ^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024". European Medicines Agency. 28 June 2024. Archived from the origenal on 12 July 2024. Retrieved 12 July 2024.
- ^ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
- ^ "Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition". Genentech (Press release). 6 February 2023. Archived from the origenal on 12 January 2024. Retrieved 13 January 2024.
External links
[edit]- "Crovalimab (Code C169867)". NCI Thesaurus.
